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Malaria in pregnancy in the Asia-Paciﬁ c region
Marcus J Rijken, Rose McGready, Machteld E Boel, Rini Poespoprodjo, Neeru Singh, Din Syafruddin, Stephen Rogerson, François Nosten
Most pregnant women at risk of for infection with Plasmodium vivax live in the Asia-Paciﬁ c region. However, malaria in 
pregnancy is not recognised as a priority by many governments, policy makers, and donors in this region. Robust data for 
the true burden of malaria throughout pregnancy are scarce. Nevertheless, when women have little immunity, each 
infection is potentially fatal to the mother, fetus, or both. WHO recommendations for the control of malaria in pregnancy 
are largely based on the situation in Africa, but strategies in the Asia-Paciﬁ c region are complicated by heterogeneous 
transmission settings, coexistence of multidrug-resistant Plasmodium falciparum and Plasmodium vivax parasites, and 
diﬀ erent vectors. Most knowledge of the epidemiology, eﬀ ect, treatment, and prevention of malaria in pregnancy in the 
Asia-Paciﬁ c region comes from India, Papua New Guinea, and Thailand. Improved estimates of the morbidity and 
mortality of malaria in pregnancy are urgently needed. When malaria in pregnancy cannot be prevented, accurate 
diagnosis and prompt treatment are needed to avert dangerous symptomatic disease and to reduce eﬀ ects on fetuses. 
Introduction
Most pregnant women at risk for infection with 
Plasmodium vivax live in the Asia-Paciﬁ c region, which 
consists of the WHO South-East Asia and Western Paciﬁ c 
regions. These areas generally have low transmission of 
Plasmodium falciparum and women have little acquired 
immunity against malaria.1 Many countries in the Asia-
Paciﬁ c region have successfully reduced prevalence of 
malaria and several national malaria control programmes 
have adopted elimination of malaria as an objective. 
However, malaria infection in pregnancy is commonly 
not perceived as a major health problem. Pregnant 
women are a vulnerable population,2 but in many areas 
their malaria-related morbidity and mortality are 
unknown.3 Speciﬁ c treatment guidelines or prevention 
strategies for malaria in pregnancy either do not exist or 
have only recently been introduced.4–6 
Interventions recommended by WHO for the control of 
P falciparum malaria during pregnancy are largely based 
on ﬁ ndings from sub-Saharan Africa, where P falciparum 
is the dominant species, transmission is high, and 
Anopheles gambiae is the main vector.7 Strategies for the 
Asia-Paciﬁ c region are complicated by several factors: 
diversity in malaria transmission and vector behaviour,8 
coexistence of P vivax,9 multidrug-resistant parasites,10,11 
substandard and counterfeit drugs,12 cross-border move-
ment of migrants,2 ethnic minorities that have little access 
to health care,2 and the political climate in some countries.2 
In this Review of the 20 countries in the Asia-Paciﬁ c region 
with malaria transmission,13 we summarise both published 
(126 reports) and unpublished (six studies) data for malaria 
in pregnancy identiﬁ ed from various databases and the 
World Malaria Report14 (webappendix pp 1–4), focusing on 
epidemiology, clinical presentation, treatment, and 
prevention of malaria in pregnancy. Additionally, we 
identify gaps in the evidence to assist identify priorities for 
future research in the Asia-Paciﬁ c region. 
Epidemiology
Malaria transmission
Malaria transmission in the Asia-Paciﬁ c region is highly 
hetero geneous. Generally, transmission is low (entomo-
logical inoculation rate of P falciparum is less than one 
infective bite every year), unstable (with year-to-year 
variation and epidemics), highly focal, and seasonal, 
and it mostly occurs in rural areas.15 Nonetheless, 
several countries have foci of entomological inoculation 
rates of more than ten infectious bites per year, 
indicating high transmission.16 Of the total population 
at risk (more than 2·2 billion people), a quarter lives in 
areas of moderate or high P falciparum malaria 
transmission.1,13,17 Large vari ations in malaria 
transmission are present not only within countries, but 
also within regions. For example, malaria in Thailand 
occurs in forested pockets along international 
borders.18,19 Urban malaria is rare, except in India.3,20 All 
these variations have important eﬀ ects on the 
acquisition of natural immunity to malaria. P vivax 
malaria could re-emerge in areas where it was 
eliminated21 or become prevalent where P falciparum is 
controlled.19,22 The prevalence of P vivax is diﬃ  cult to 
estimate because P vivax is often under-reported in co-
infections with P falciparum and relapses from liver 
stages are unrelated to vector activity.23,24 
Pregnancies at risk
In 2007, roughly 75 million women became pregnant in 
the Asia-Paciﬁ c region,1 but these women were mostly 
in India and China. Because of the focal nature of 
malaria transmission,25 the substantial seasonality, and 
the variable strength of malaria control programmes, 
risk estimates have to be reﬁ ned and combined with 
clinical data to be accurate and useful, and to minimise 
bias. In pregnancy, women and their babies are at risk 
of malaria’s deleterious eﬀ ects for the 40 weeks of 
gestation. However, longitudinal data collection is 
needed to estimate the true burden of malaria. Most 
investigators report rates of conﬁ rmed malaria infection 
at enrolment in the antenatal clinic (table 1) or at delivery 
(table 2); only a few record cumulative proportions or 
incidence rates. 
Four studies27–29,32 that showed a high proportion of 
women with malaria (three from India and one from 
Laos) included only pregnant women with fever or a 
See Online for webappendix
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history of fever. After exclusion of these studies, malaria 
smears to detect parasites in maternal peripheral blood 
established that the median reported proportion of 
pregnant women infected with malaria was 15·3% 
(range 1·2–40·8) in antenatal clinics (nine studies; 
webappendix p 5) and 8·1% (range 1·6–18·5) in delivery 
rooms (12 studies; webappendix p 7). The median 
proportion of reported placental parasitaemia was 
11·0% (range 1·4–29·1; 12 studies; webappendix p 8). 
Screening surveys, however, are very prone to 
variation because they provide only an estimate of the 
prevalence of malaria infections in a short period. The 
wide range of positivity rates is a result not only of 
diﬀ erences in transmission intensity, but also of 
discrepancies in methods or season when surveys are 
done. For example, at antenatal screenings every week 
at the Thai-Burmese border, which are essentially 
weekly cross-sectional surveys, the mean malaria 
prevalence in one clinic was 0·85% (95% CI 0·83–0·87; 
range 0–3·1) for P falciparum and 3·18% (95% CI 
3·14–3·22; range 0–8·3) for P vivax in 2008 (un-
published). However, the cumulative proportions of 
infected women in the same population in the same 
year were 6·8% (50 of 733 women) for P falciparum and 
16% (119 of 733 women) for P vivax (unpublished). In 
this setting in 2008, the median number of consultations 
per woman was 14 (IQR 8–20).
To establish the true burden of malaria in pregnancy, 
longitudinal follow-up of pregnant women is preferable. 
Investigators of 11 studies have followed up the same 
women during pregnancy, providing a cumulative 
proportion of malaria episodes (table 3). In ten studies 
that showed the number of women with malaria, the 
median proportion of infected women was 36·5% 
(range 6·0–64·0). Women can be infected in all 
trimesters33,47,48 and in any pregnancy, although ﬁ rst-time 
mothers are at higher risk than are others in most 
studies.20,48 In ﬁ ve studies in India,27–29,52,53 pregnant 
Year Site Timing of 
screening
Chemoprophylaxis 
(% participants 
taking prophylaxis)
Screening 
method
Total 
women 
screened
Number with 
malaria
Infections by species
Plasmodium 
falciparum
Plasmodium 
vivax
Mixed Other 
species
South East Asian region
Bangladesh (Faiz, 
A, personal 
communication)
2004 Southeast Any ANC visit Chloroquine (2·4%) MS 388 15 (3·9%) NA NA NA NA
Burma26 2006–08 East Survey No RDT 850 100 (11·8%) 100 (100%) NA NA NA
India27 1987–88 Gujarat Surat Women with 
HOF
No MS 322 186 (57·8%) 112 (60·2%) 70 (37·6%) 4 (2·2%) 0 (0%)
India28 1991–93 Jabalpur Women with 
HOF
No MS 831 145 (17·4%) 101 (69·7%) 41 (28·3%) 3 (2·1%) 0 (0%)
India29 1991–93 Jabalpur Women with 
HOF
No MS 2127 365 (17·2%) 244 (66·8%) 121 (33·2%) 0 (0%) 0 (0%)
India30 2001–02 Nine sites NA No MS NA 215 (NA) 131 (60·9%) 69 (32·1%) 15 (7·0%) 1 (<1%)*
India20 2006–07 Jharkhand Any ANC visit Chloroquine (0·6%) MS 
RDT
2386
2386
32 (1·3%)
43 (1·8%)
NA
23 (53·5%)
NA
16 (37·2%)
NA
4 (9·3%)
0 (0%)
India 
(unpublished)
2007–08 Chhattisgarh Booking at 
ANC
No MS
RDT
2696
2696
33 (1·2%)
35 (1·3%)
NA
29 (82·9%)
NA
6 (17·1%)
NA
0 (0%)
0 (0%)
Indonesia 
(unpublished)
2008–10 Jayapura Any ANC visit No MS 1551 238 (15·3%) 138 (58·0%) 68 (28·6%) 30 (12·6%) 0 (0%)
Indonesia 
(unpublished)
2008–10 Sumba Any ANC visit No MS 1554 207 (13·3%) 139 (67·1%) 60 (29·0%) 8 (3·9%) 0 (0%)
Nepal31 1994–97 Sarlahi Enrolment No MS 288 57 (19·8%) 0 (0%) 57 (100%) 0 (0%) 0 (0%)
Western Paciﬁ c region
Laos32 1998 Vientiane Women with 
HOF
No MS 68 16 (23·5%) 16 (100%) NA 0 (0%) 0 (0%)
PNG33 1985–87 Madang First ANC Chloroquine (23%) MS 620 180 (29·0%) 170 (94·4%) 9 (5·0%) NA 1 (<1%)†
PNG 
(unpublished)
2006–08 Madang First ANC No MS
PCR
468
468
191 (40·8%)
307 (65·6%)
142 (74·3%)
217 (70·7%)
38 (20·0%)
NA
NA 11 (2·4%)*
52 (11.1%)*
Solomon34 2003 Marovo 
Lagoon
Any ANC visit Very low coverage MS 106 19 (17·9%) 15 (78·9%) 4 (21·1%) 0 (0%) 0 (0%)
Infections with P falciparum and P vivax were classed as mixed infections. ANC=antenatal clinic. MS=malaria smear. NA=not available. RDT=rapid diagnostic test. HOF=history of fever. PNG=Papua New Guinea. 
*Infection with Plasmodium ovale. †Infection with Plasmodium malariae. 
Table 1: Proportion of women with malaria in antenatal clinics by country in the Asia-Paciﬁ c region
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women with fever or a history of fever (n=974) were 
infected (with P falciparum or P vivax) signiﬁ cantly more 
frequently, with signiﬁ cantly higher parasitaemia, than 
were non-pregnant women of child-bearing age with 
fever or a history of fever in the same area and study 
period. Women with a history of malaria in pregnancy 
are at increased risk for another episode during 
pregnancy.37,38
Plasmodial species
In the reviewed studies, P vivax caused a median of 
28·5% (range 5–100) of malaria infections detected at 
antenatal clinics (13 studies; table 1). Plasmodium ovale 
and Plasmodium malariae were present in all sites, but 
studies with PCR diagnosis suggest that these species 
are probably under-reported when microscopy is used.3,54 
Plasmodium knowlesi was not reported in any pregnancy 
Year Site Chemoprophylaxis 
(% participants 
taking prophylaxis)
Screening method Total 
women
Number with 
malaria
Infections by species
Plasmodium 
falciparum
Plasmodium vivax Mixed Other species
South East Asian region
India29 1992–95 Jabalpur No Maternal MS* 2127 365 (17·2%) 244 (66·8%) 121 (33·2%) 0 (0%) 0 (0%)
India35 2002–03 Mandla No Placental MS/RDT 182 53 (29·1%) 49 (95·5%) 1 (1·9%) 3 (5·7%) 0 (0%)
India36 2002–04 Mandla
Mandla
Mandla
Maihar
Maihar
Maihar
No Maternal MS
PlacentalMS
Placental RDT (PC)
Maternal MS
Placental MS
Placental RDT (PH)
209
209
209
590
590
590
11 (5·3%)
30 (14·4%)
56 (26·8%)
41 (6·9%)
64 (10·8%)
65 (11·0%)
7 (63·6%)
26 (86·7%)
56 (100%)
29 (70·7%)
54 (84·4%)
65 (100%)
0 (0%)
0 (0%)
NA
10 (24·4%)
8 (12·5%)
NA
4 (36·4%)
4 (13·3%)
NA
2 (4·9%)
2 (3·1%)
NA
0 (0%)
0 (0%)
NA
0 (0%)
0 (0%)
NA
India20 2006–07 Jharkhand
Jharkhand
Jharkhand
Chloroquine (0·3%) Maternal MS/RDT
Placental MS
Placental RDT
717
712
712
12 (1·7%)
10 (1·4%)
17 (2·4%)
9 (75·0%)
NA
12 (70·6%)
2 (16·7%)
NA
2 (11·8%)
1 (8·3%)
NA
3 (17·6%)
0 (0%)
NA
0 (0%)
India 
(unpublished)
2007–08 Chhattisgarh
Chhattisgarh
Chhattisgarh
Chhattisgarh
No Maternal MS 
Maternal RDT
Placental MS
Placental RDT
1028
1028
1027
1027
16 (1·5%)
19 (1·8%)
17 (1·7%)
33 (3·2%)
NA
13 (68·4%)
NA
18 (54·5%)
NA
5 (26·3%)
NA
12 (36·4%)
NA
1 (5·3%)
NA
3 (9·1%)
NA
0 (0%)
0 (0%)
0 (0%)
Indonesia37 2004–06 Timika No Maternal MS 2487 397 (16·0%) 225 (56·7%) 141 (35·5%) 12 (3·0%) 18 (4·5%)†; 
1 (<1%)‡
Indonesia 
(unpublished)
2008–10 Jayapura
Jayapura
Sumba
Sumba
NA Maternal MS
Placental MS
Maternal MS
Placental MS
830
818
981
974
90 (10·8%)
75 (9·2%)
112 (11·4%)
109 (11·2%)
55 (61·1%)
46 (61·3%)
72 (64·3%)
68 (62·3%)
29 (32·2%)
24 (32·0%)
35 (31·3%)
36 (33·0%)
2 (2·2%)
3 (4%)
5 (4·5%)
5 (4·6%)
4 (4·4%)‡
2 (2·7%)‡
0 (0%)
0 (0%)
Thailand38 2004–06 TBB
TBB
TBB
TBB
No Maternal MS§
Maternal PCR§
Placental MS§
Placental PCR§
169
169
156
168
8 (4·7%)
5 (3·0%)
7 (4·5%)
6 (3·6%)
5 (62·5%)
5 (100%)
6 (85·7%)
6 (100%)
3 (37·5%)
NA
1 (14·3%)
NA
0 (0%)
NA
0 (0%)
NA
0 (0%)
NA
0 (0%)
NA
Thailand39 1995–2002 TBB
TBB
TBB
No Maternal MS§
Placental MS§
Placental 
histopathology§
175
173
174
19 (10·9%)
12 (6·9%)
37 (21·3%)
12 (63·2%)
11 (91·7%)
NA
7 (36·8%)
1 (8·3%)
NA
0 (0%)
0 (0%)
NA
0 (0%)
0 (0%)
NA
Western Paciﬁ c region 
PNG40 1986–88 East Sepik
East Sepik
No chloroquine past 
2 weeks
Maternal MS
Placental MS
83
83
7 (8·4%)
16 (19·3%)
6 (85·7%)
16 (100%)
1 (14·3%)
0 (0%)
NA
NA
NA
NA
PNG41 1994–96 Madang
Madang
Chloroquine (92·2%) Maternal MS
Placental MS
987
860
183 (18·5%)
206 (24·0%)
NA
NA
NA
NA
NA
NA
NA
NA
PNG42 2002–03 Madang
Madang
Madang
Chloroquine high 
compliance low 
eﬃ  cacy
Maternal MS
Placental MS
Placental 
histopathology
402
402
192
63 (15·7%)
66 (16·4%)
81 (42·2%)
59 (93·7%)
63 (95·5%)
NA
4 (6·3%)
3 (4·5%)
NA
0 (0%)
0 (0%)
NA
0 (0%)
0 (0%)
NA
PNG 
(unpublished) 
2006–08 Madang
Madang
SP and chloroquine; 
chloroquine weekly 
Maternal MS
Maternal PCR
331
331
25 (7·6%)
140 (42·3%)
20 (80·0%)
102 (72·9%)
5 (20·0%)
NA
0 (0%)
NA
0 (0%)
4 (2·9%)‡
Solomon 
Islands43
1981 Malaita
Malaita
Chloroquine 
(9%)
Maternal MS
Placental MS
180
180
14 (7·8%)
10 (5·6%)
12 (85·7%)
9 (90·0%)
2 (14·3%)
1 (10·0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
Vanuatu44 1984–85 Malekula NA Placental MS 184 20 (10·9%) 10 (50·0%) 10 (50·0%) 0 (0%) 0 (0%)
Infections with P falciparum and P vivax were classed as mixed infections. MS=malaria smear. RDT=rapid diagnostic test. PC=Paracheck. NA=not available. PH= ParaHITf. TBB=Thai-Burmese border. PNG=Papua 
New Guinea. SP=sulfadoxine-pyrimethamine. *History of fever. †Infection with Plasmodium malariae. ‡Infection with Plasmodium ovale. §All women had at least one malaria infection in pregnancy.
Table 2: Proportion of women with malaria at delivery by country in the Asia-Paciﬁ c region 
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studies. At the Thai-Burmese border, the incidence of 
malaria has fallen from more than three infections per 
pregnant woman-year to less than 0·5 in the past 
20 years,22 and distribution of malaria species has 
changed substantially (ﬁ gure 1, table 3). Most malaria 
infections are now caused by P vivax,9,48,50,51 and mixed 
infection is uncommon (tables 1–3). A protective eﬀ ect 
of P vivax infection against subsequent episodes and 
severity of P falciparum malaria was noted in Thailand.9,55 
However, an acute episode of P falciparum could trigger 
a relapse of a previously acquired P vivax infection.56 
Therefore, as the incidence of P falciparum declines, the 
number of P vivax episodes caused by relapses will 
eventually also decrease.
Clinical presentation
Diagnosis
The most common method used to detect malaria 
parasites is microscopy of stained blood smears 
(tables 1–3). A skilled and well-equipped microscopist 
can detect 15 parasites per μL of blood, which 
corresponds to a total biomass of 100 million parasites.57 
In ﬁ eld situations, however, equipment might not be 
ideal and experienced microscopists are often 
overloaded with work. No published data exist for 
quality control of malaria smears from pregnant 
women. Rapid diagnostic tests are practical because 
they do not demand long training, good infrastructure, 
or electricity, but they might not have the sensitivity 
needed in pregnancy.36,57 Studies done in Jharkhand and 
Chhattisgarh states in India showed that rapid 
diagnostic tests were more sensitive than were malaria 
smears for the detection of malaria in the peripheral 
blood of women in labour and in placental infection 
(table 2).36 However, these ﬁ ndings could be explained 
by the slow elimination of the histidine-rich-protein-2 
detected by the Paracheck-Pf rapid diagnostic test 
used. 
PCR is also used for genotyping and detection of malaria 
parasites and is more sensitive than is microscopy.57 At 
present, there is very little evidence for PCR diagnostic 
assessment in pregnancy in the Asia-Paciﬁ c region. In 
available studies, PCR detected more P falciparum than 
did malaria smear (tables 1, 2). Continuing studies in 
India (Madhya Pradesh and Chhattisgarh states) and 
eastern Indonesia showed that PCR detected up to twice 
as many P vivax and P falciparum episodes as did malaria 
smears or rapid diagnostic tests (unpublished). 
In areas with early detection and treatment with 
artemisinin-based combination therapies, placental 
malaria is conﬁ ned to pregnancies with concurrent 
maternal peripheral parasitaemia.38,39 Furthermore, sites 
at the Thai-Burmese border and Indonesia that use 
artemisinin-based combination therapies in pregnancy 
have a lower ratio of placental to peripheral smear 
positivity than do sites in India and Papua New Guinea, 
where chloroquine or sulfadoxine-pyrimethamine, or 
both, are used (table 2, ﬁ gure 2). In India and Papua 
New Guinea, P falciparum resistance to chloroquine 
and sulfadoxine-pyrimethamine is high.20,29,35,36,40,41,42 
Despite diﬀ erences in transmission, this ﬁ nding could 
be a result of increased clearance of parasites from the 
maternal and placental blood by the more eﬀ ective 
artemisinin-based combination therapies. 
Year Site Frequency of 
malaria smear
Total 
women 
screened
Cumulative 
proportion 
with malaria
Total 
malaria 
episodes
Infections by species
  Plasmodium 
falciparum 
Plasmodium 
vivax 
Mixed Other 
species
India45 1995–96 Mandla Every 2 weeks* 150 96 (64·0%) NA NA NA NA NA
India46 NA Orissa Every 2 weeks 209 NA 92 NA NA NA NA
India47 1997–98 Mandla Every 2 weeks† 274 151 (55·1%) 237 202 (85·2%) 27 (11·4%) 8 (3·4%) 0 (0%)
India 
(unpublished) 
2007–08 Jabalpur Every month 1742 105 (6·0%) 119 88 (73·9%) 31 (26·1%) 0 (0%) 0 (0%)
Thailand48 1986–89 TBB Every week 1358 505 (37·2%) 888 712 (80·2%) 152 (17·1%) 24 (2·7%) 0 (0%)
Thailand49* 1987–90 TBB Every week 169 37 (21·9%) 89 62 (69·7%) 21 (23·6%) 5 (5·6%) 1 (1·1%)‡
Thailand9 1986–97 TBB Every week 9956 2509 (25·2%) 2509 1402 (55·9%) 634 (25·3%) 473 (18·9%) 0 (0%)
Thailand50 1993–96 TBB Every week 1495 555 (37·1%) 1096 491 (44·8%) 570 (52·0%) 34 (3·1%) 0 (0%)
Thailand51 1998–2000 TBB Every week§ 479 57 (11·9%) 163 78 (47·9%) 83 (50·9%) NA 2 (<1%)‡
Thailand 
(unpublished)
2007–10 TBB Every week 824 319 (38·7%) 772 174 (22·5%) 592 (76·7%) 4 (0·5%) 1 (<1%)‡; 
1 (<1%)¶ 
Thailand 
(unpublished)
2009–11 TBB Every week 100 36 (36·0%) 97 10 (10·3%) 85 (87·6%) 2 (2·1%) 0 (0%)
Chemoprophylaxis was not used in these studies. Infections with P falciparum and P vivax were classed as mixed infections. NA=not available. TBB=Thai-Burmese border. 
*Pregnant women with history of fever. †During a malaria epidemic. ‡Infection with Plasmodium malariae. §Placebo group in a randomised controlled trial. ¶Infection with 
Plasmodium ovale. 
Table 3: Longitudinal follow-up of pregnant women with malaria by country in the Asia-Paciﬁ c region
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Anaemia
The anaemia burden in pregnancy is profound: about 
75% of women attending antenatal clinics in India,20,47 
Nepal,31 Papua New Guinea,58 or at the Thai-Burmese 
border50 develop anaemia at some stage of pregnancy. 
Malaria-induced destruction of red blood cells aggravates 
any underlying nutritional anaemia, intestinal para-
sitisation, or red-cell inherited disorders such as haemo-
globinopathies.15 In low-transmission areas, mild 
anaemia predominates, whereas in areas of high 
transmission, 10% of pregnant women might develop 
severe anaemia.48,50,58,59
Comparisons between studies are diﬃ  cult because of 
diﬀ erences in anaemia deﬁ nitions, iron supple-
mentation, and use of chemoprophylaxis. Both 
falciparum and vivax malaria worsen anaemia, but 
P falciparum has a stronger eﬀ ect than does P vivax 
(webappendix p 9).9,31,37,60 Even asymptomatic malaria 
episodes could cause anaemia,37 and women during 
their second or subsequent pregnancies are more 
anaemic than are women in their ﬁ rst pregnancy.37,42,48,50 
Severe maternal anaemia during pregnancy increases 
risk of premature labour37,41 and stillbirth,61,62 and reduces 
birthweight.37,48,58 
Data from Thailand suggest that risk of P vivax malaria 
increases after start of haematinic supplementation 
(iron and folate).63 Deﬁ ciency of glucose-6-phosphate 
dehydro genase is common in the Asia-Paciﬁ c region, 
but its interaction with the risk of malaria in pregnant 
women and anaemia is unknown. Although southeast 
Asian ovalocytosis and α thalassaemia protect young 
children in Papua New Guinea against cerebral 
malaria,64,65 neither genetic trait seems to change the 
eﬀ ects of malaria in pregnancy.42,59,66 The risk of 
thrombocytopenia is more than two times higher in 
pregnant women with malaria than in non-pregnant 
women infected with malaria, but this disorder is rarely 
severe (less than 10 000 platelets per μL).60,67 Prompt 
antimalarial treatment can normalise platelet counts 
within a week.67 Malaria-induced thrombocytopenia and 
anaemia could increase the risk of post-partum 
haemorrhage.68 
Comorbidities
A relation between placental malaria and pre-eclampsia 
is suggested by studies from highly endemic areas,69 
but only one report is from the Asia-Paciﬁ c region after 
an epidemic in 1935.70 In sub-Saharan Africa, the 
burden of malaria has been exacerbated by HIV.71 No 
reports of HIV and malaria in pregnancy come from 
the Asia-Paciﬁ c region. Investigators have recorded an 
association between low rates of P falciparum or P vivax 
infection in pregnant women and co-infection with 
Ascaris lumbricoides.72 Hookworm infestation, however, 
is associated with an increased risk of P falciparum 
infection and low birthweight, and high hookworm 
counts are linked with anaemia.72–74 An integrated 
approach to malaria and helminth control has been 
promoted for pregnant women75 and should be tailored 
according to the local prevalence and intensity of 
geohelminths and malaria, and anaemia burden.72 
About 10% of women with malaria had rickettsial co-
infection in a cohort study done at the Thai-Burmese 
border.76
Severe malaria and mortality
Detailed malaria-attributable maternal mortality rates 
are rarely reported. However, in three districts in India, 
22 (23%) of 95 maternal deaths were attributed to malaria 
between 2004 and 2006, which is a total mortality rate of 
722 per 100 000 livebirths.77 Malaria was the most 
Figure 1: Annual cumulative proportion of women infected with malaria during pregnancy at the 
Thai-Burmese border
n=48 410. 
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common cause of maternal death during pregnancy 
(11 of 23 deaths; 48%) and was the cause of six (23%) of 
26 post-partum maternal deaths. Before introduction of 
malaria-control programmes for pregnant women in 
western Thailand, ﬁ ve (1%) of 500 pregnant women died 
of malaria in 1 year.48 Signs that are rare in childhood 
malaria—eg, acute renal failure, pulmonary oedema, 
and severe jaundice—are common manifestations of 
severe malaria in adults.55,78 Death during pregnancy or 
just after delivery occurs because of cerebral malaria, 
renal failure, hepatic impairment, severe anaemia, 
hypoglycaemia (worse with quinine treatment), 
uncontrollable post-partum haemorrhage, or acute 
respiratory distress syndrome.30,48,70,78–80 
Pregnant women have a three-times higher risk of 
severe malaria than do non-pregnant women.53,55 In eight 
studies of severe malaria in pregnancy (n=227),52,78–84  the 
median maternal mortality was 39% (range 8–100). This 
wide range is related to the broad WHO deﬁ nition of 
severe malaria: the lowest mortality was reported in 
pregnant women whose only sign of severity was 
hypoglycaemia.79 By contrast, all women with renal failure 
died.78 In an autopsy study of 277 women in India,85 10% 
of maternal mortality was attributable to infectious 
diseases, of which tuberculosis, malaria, and leptospirosis 
were most common. In reports from India,35,60,86 women 
with severe vivax malaria had very poor pregnancy 
outcomes and maternal mortality was reported. An action-
for-survival programme dedicated to care of pregnant 
women with malaria greatly reduced mortality in a 
regional hospital in Thailand, where malaria was the most 
common cause of maternal death during the 1980s.87 Early 
detection and treatment at the Thai-Burmese border has 
eliminated maternal death and severe malaria in women 
who participate in weekly screening.48
Eﬀ ect on fetuses and infants
The median reduction in birthweight in the reviewed 
studies was 150 g (range 1–650; ﬁ gure 3) for P falciparum 
or mixed infections,20,29,36,37,41,42,44,47,48,88,89 and 108 g (107–310) 
for P vivax malaria.9,29,37 Birthweight reduction occurs 
mainly in ﬁ rst pregnancies with P falciparum malaria but 
also in subsequent pregnancies, and even with one 
episode of P vivax or P falciparum malaria.9,39,48 Both 
symptomatic and asymptomatic malaria episodes 
increase the risk of low birthweight, although 
symptomatic infections in pregnancy might have a larger 
eﬀ ect than does asymptomatic disease, particularly on 
premature delivery.37,48,50 Malaria reduces birthweight 
independently of anaemia.58 Macgregor90 identiﬁ ed an 
exponential fall in the risk ratio for low birthweight in 
women during their ﬁ rst pregnancy after a reduction in 
malaria transmission in the Solomon Islands. This 
Review does not address how malaria reduces birthweight, 
particularly with P vivax, which does not seem to 
cytoadhere in the placenta to the same extent as 
P falciparum. 
Low birthweight alone is not a reliable indicator of 
malaria’s eﬀ ect on fetal growth; other information is 
needed, such as parents’ anthropometrics, gestational 
age, neonatal length, and head circumference.91 
Gestational age estimation is notoriously diﬃ  cult in 
resource-poor settings. In the studies shown in ﬁ gure 3, 
neither ultrasound dating (early gestation ultrasound is 
the gold standard for gestational age estimation) nor fetal 
size charts to diagnose intrauterine growth restriction 
were available.91 
Fetal distress (measured by cardiotocography or 
meconium staining of the amniotic ﬂ uid) is an 
important feature of symptomatic falciparum malaria 
and severe anaemia, both before and during labour.62,79 
In areas where women attend antenatal clinics late in 
pregnancy or only for delivery, miscarriage rates are 
probably underestimated. Stillbirth and spontaneous 
abortion can result from infection with P falciparum or 
P vivax, and from severe anaemia.27,37,58,61,62,80 However, in 
an early report9 from an intense antenatal malaria 
screening and prompt-treatment programme at the 
Thai-Burmese border, P vivax infection was not 
associated with premature labour, miscarriage, or 
stillbirth. By contrast, of 25 unwell Indian pregnant 
women admitted to hospital because of P vivax malaria, 
more than half of the pregnancies ended with these 
adverse outcomes.60 This ﬁ nding draws attention to the 
importance of early detection and treatment of any 
malaria in pregnancy to prevent the eﬀ ects of 
symptomatic disease. Further studies into eﬀ ects of 
malaria infection in the ﬁ rst trimester are needed. 
Congenital malaria occurs when malaria parasites cross 
the placenta either during pregnancy,92 or at delivery.93 
Congenital P falciparum or P vivax malaria is a potentially 
serious complication of symptomatic and asymptomatic 
infection at any time in pregnancy, but neonatal symptoms 
are not typical for malaria and usually become evident 
only 10–30 days after birth.92,93 Table 4 shows prevalence of 
congenital malaria. There are no WHO criteria for 
diagnosis or recommendations for drug dosing in 
treatment of neonates with severe malaria. Severe disease 
in neonatal P falciparum and P vivax infections is common 
and can be characterised by severe anaemia and 
respiratory distress. All sick neonates in malaria endemic 
regions should have a malaria smear.92,96,102 
Additionally, malaria in pregnancy directly aﬀ ects infant 
survival. In Thailand, maternal infection (including 
malaria) in the week before delivery is the only risk factor 
for infant death in the ﬁ rst 3 months of life, after 
adjustment for birthweight and gestational age.50 Anaemia 
was an independent risk for infant death in early studies 
in Thailand,49,106 but a 2001 investigation did not conﬁ rm 
this ﬁ nding.50 This diﬀ erence might be explained by the 
multifactorial causes of anaemia in Thailand and co-
deﬁ ciency of vitamin B₁ in infants, a major cause of infant 
mortality.107 Although treatment38 and prevention51 for 
malaria had no adverse eﬀ ects on infant growth and 
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neurodevelopment at age 1 year in a study in Thailand, no 
studies of the interaction with nutritional status, child 
development, and the placental and fetal epigenome exist. 
However, high rates of childhood stunting were reported 
in Papua New Guinea in individuals exposed to malaria 
in utero during an epidemic.108 
Treatment
The Asia-Paciﬁ c region has been aﬀ ected by the emergence 
of antimalarial-drug resistance.10,11,37,109 Most countries have 
updated their national guidelines to match WHO 
recommendations of artemisinin-based combination 
therapies in the second and third trimester of pregnancy. 
Proactive operational guidelines include use of artemisinin-
based combination therapies in pregnancy in parts of 
Melanesia for both P falciparum and P vivax.37 Trials of 
antimalarials in pregnancy for infection with P falciparum 
and P vivax have been done (table 5), but most occurred in 
one site only. No researchers have randomly assigned 
pregnant women in the ﬁ rst trimester.
No large recent studies of chloroquine eﬃ  cacy in 
treatment of vivax malaria in pregnancy are available,113,121 
but Indonesia, the Solomon Islands, Papua New 
Guinea, and Vanuatu have changed their national 
treatment to artemisinin-based combination therapies 
because of the high prevalence of chloroquine-resistant 
parasites in the general population.122 P vivax has liver 
stages (hypnozoites) that cause recurrent blood stage 
infections (relapses). Primaquine—the only drug 
eﬀ ective against liver stages—is contraindicated in 
pregnant and lactating women because fetal red blood 
cells are susceptible to haemolysis.123 Chloroquine 
remains the drug of choice for uncomplicated P knowlesi, 
P malariae, and P ovale.124 
In a small pharmacokinetic study in Papua New 
Guinea,120,121 13 women were treated with a combination 
of sulfadoxine-pyrimethamine and chloroquine, which 
had a low cure rate of 62% (table 5). Chloroquine had 
no eﬀ ect against P falciparum in pregnant women in 
India during a malaria epidemic in 1997–98.47 The mean 
cure rate of quinine monotherapy in seven studies 
(845 patients; table 5) was 73·2% (SD 14·1), probably 
because of resistance and, in one study,48 poor adherence 
to treatment. When clindamycin was added to quinine 
and treatment was supervised,116 cure rate improved to 
100%. However, the gametocyte carriage rate after 
treatment in women who did not have these sexual 
stages on admission was 13 times higher than it was in 
women given a 7 day course of artesunate monotherapy.109 
Meﬂ oquine monotherapy had a cure rate of  72% in one 
investigation,111 but in combination with artesunate it 
can reach 100%.112,115 In a study at the Thai-Burmese 
border,38 125 pregnant women treated with artemether-
lumefantrine for 3 days had a cure rate of only 87%, 
which was inferior to artesunate monotherapy for 
7 days. Other artemisinin-based combination therapies 
(dihydro artemisinin-piperaquine; artesunate-clinda-
mycin; and artesunate, atovaquone, and proguanil) 
have cure rates of more than 90% (table 5). Treatment 
of severe malaria in pregnant women has not been 
investigated, although these patients were not excluded 
from the SEAQUAMAT trial.84 However, intravenous 
artesunate is the WHO recommended treatment of 
choice, irrespective of trimester.84,125 
In practice, health workers providing antimalarials 
either might not prescribe correct doses126 or might be 
afraid to give drugs to pregnant women because of 
concerns about potential teratogenic eﬀ ects or 
abortion.126,127 Recommendations about regimens to use 
in treatment of malaria during pregnancy are notably 
absent in many settings.128 A major disconnect has been 
identiﬁ ed between routine antenatal practices and 
known strategies to prevent and treat malaria in 
pregnancy.128 
13 (62%) of 21 studies into antimalarial pharma-
cokinetics in pregnancy worldwide have been done in 
the Asia-Paciﬁ c region. Many drugs have been studied: 
quinine;129 meﬂ oquine;130,131 chloroquine;132,133 sulfa doxine-
pyri methamine;134 artemether-lumefant rine;135,136 pro-
guanil;137,138 artesunate;139 atovaquone and proguanil;140 
and azithromycin.141 Several researchers report reduced 
drug concentrations in pregnant women’s blood after 
standard dosing of antimalarial drugs and recommend 
the need for dose alterations, especially for lumefantrine, 
chloroquine, and proguanil. 
Prevention
Unlike sub-Saharan Africa, prevention of malaria in 
pregnancy is not emphasised in national guidelines for 
malaria in the Asia-Paciﬁ c region. Longlasting 
Figure 3: Reported mean diﬀ erence in birthweight after malaria-infected and uninfected pregnancies
Birthweight diﬀ erences are shown as mean (95% CI when available). Primip=primiparous women. 
Multip=multiparous women. np=not published.
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insecticide-treated bednets are distributed in all 
countries,14 but reports in the past 3 years have shown 
low availability or use by pregnant women.26,34,128 Case 
management is available everywhere, but in reality 
malaria smears are obtained from pregnant women only 
when fever or other malarial symptoms are present and 
these symptoms are often not checked by health 
workers.128 Papua New Guinea is the only country with a 
policy for intermittent preventive treatment in pregnancy. 
However, the policy has yet to be implemented in 
antenatal clinics. More than 10 years have passed since 
the reduction in incidence of P falciparum in pregnant 
women at the Thai-Burmese border because of early 
detection and treatment of the general population with 
artemisinin-based combination therapies (eg, 
meﬂ oquine-artesunate).22 These factors have had a far 
greater eﬀ ect than have chemoprophylaxis,49 bednets,106 
or skin repellents for pregnant women.142 
Study 
type
Number 
of 
neonates 
tested
Number with malaria at 
birth
Number with malaria at 
1–7 days
Number with malaria at 
8 days–1 month
Number with malaria at 
1–3 months
Maternal 
malaria
Parasite 
discordance
Plasmodium 
falciparum
Plasmodium 
vivax
Plasmodium 
falciparum
Plasmodium 
vivax
Plasmodium 
falciparum
Plasmodium 
vivax
Plasmodium 
falciparum
Plasmodium 
vivax
South East Asia region
Sri Lanka 
(1982)94 
Case report 1 ·· ·· ·· ·· ·· ·· ·· 1* History of 
MIP
NA
India 
(1995)95
Case report 1 ·· ·· ·· ·· ·· ·· ·· 1* HOF in ﬁ rst 
trimester
NA
India 
(1998)45
Prospective 100 ·· ·· ·· ·· 1* ·· ·· ·· Persistent 
parasitaemia
None
Thailand 
(2004)39
Prospective 175 2* ·· ·· ·· ·· 1* ·· ·· Positive for 
placental 
malaria
None
Thailand 
(2006)93
Review 27 5† 20† ·· 2* ·· ·· All mothers 
had history 
of MIP
NA
India 
(2007)96
Case report 1 ·· ·· ·· ·· ·· ·· ·· 1* Peripheral 
P vivax and 
HOF
None
Thailand 
(2007)97
Review 15 2† ·· 1* ·· 3* 3* 1* 5 (1†) HOF, except 
in one case
NA
India 
(2010)98
Case report 1 ·· ·· ·· ·· ·· 1* ·· ·· History of 
MIP
NA
India 
(2010)99
Case report 1 ·· ·· ·· ·· ·· 1* ·· ·· Peripheral 
P falciparum 
and P vivax
None
India 
(2010)100
Case report 1 ·· ·· ·· ·· ·· 1* ·· ·· History of 
MIP
NA
India 
(2010)101
Case report 1 ·· ·· ·· ·· ·· ·· 1* ·· History of 
MIP
NA
Indonesia 
(2010)92,102
Cross-sectional 4884 29 (1*) 6†‡ ·· ·· ·· ·· ·· ·· 29 pregnant 
women had 
parasitaemia
5 cases
Western Paciﬁ c region
Malaysia 
(1980)103
Case report 1 ·· ·· ·· ·· ·· ·· 1* ·· Placental 
and 
peripheral 
P falciparum
None
Solomon 
Islands 
(1983)43
Cross-sectional 180 1† ·· ·· ·· ·· ·· ·· ·· Peripheral 
P falciparum
None
PNG 
(1986)104 
Case report 1 ·· ·· ·· ·· ·· 1* ·· ·· Peripheral 
P vivax
None
PNG 
(1988)105
Case-control 52 4† ·· ·· ·· ·· ·· ·· ·· Peripheral 
P falciparum
None
MIP=malaria in pregnancy. NA=not available. HOF=history of fever. PNG=Papua New Guinea. *Symptomatic. †Asymptomatic. ‡Additionally, one Plasmodium ovale and two mixed cases of P falciparum and 
P vivax reported. 
Table 4: Congenital malaria by country in the Asia-Paciﬁ c region
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Vector-control measures aiming for total-population 
coverage are beneﬁ cial for pregnant women. Insecticide-
treated bednets and indoor residual spraying reduce 
malaria transmission.143 In the only vector-control 
investigation in pregnancy in the Asia-Paciﬁ c region—a 
bednet study—fewer women in the experimental group 
had peripheral parasitaemia than in the group with 
untreated nets, but the diﬀ erence was not signiﬁ cant.106,144 
The parasite density and frequency of anaemia was lower 
in the pregnant women with treated nets than in those 
with untreated nets. No eﬀ ect on birthweight or 
premature labour was recorded.106 
In India’s Jharkhand state, most women report having 
untreated bednets in their homes, but only 3·3% had 
insecticide-treated bednets.20 Several studies show that 
free treated nets for pregnant women have not been 
distributed despite government policy, that women in 
their ﬁ rst pregnancy are less likely to own treated bednets 
than are those in subsequent pregnancies, and that 
priority to sleep under the treated net is given to young 
children.34,127,145,146 Most mosquito vectors in the Asia-Paciﬁ c 
region have exophilic and exophagic behaviour. Moreover, 
these mosquitoes are most active in the early evening, 
when most pregnant women are not under nets, or at 
Year Study type Length of 
follow-up 
(days)
Drug Sample 
size
Cure rate (%)* Conclusion or concerns
Plasmodium falciparum
Burma110 1985–86 RCT 7 Amodiaquine 19 100% Very short follow-up
India47 1997–98 Observational 35 Chloroquine 21 5% (0–13·9) Eﬃ  cacy <90%
TBB48 1997–98 Observational 28 Quinine 405 77·5% Poor compliance to 7 day treatment 
TBB111 1992–96 Observational 42 Quinine 93 77% Eﬃ  cacy <90%
TBB112 1995–97 RCT 63 Quinine 43 67·0% (43·3-90·8) Eﬃ  cacy <90%; AE ↑
TBB113 1995–2000 Observational 42 Quinine 209 71·3% Eﬃ  cacy <90%; quinine safe in ﬁ rst 
trimester; AE ↑
TBB113 2002 Observational 42 Quinine 25 56% Treatment of repeat P falciparum; 
eﬃ  cacy <90%
TBB114 2001–03 RCT 63 Quinine 41 63·4% (46·9–77·4) Unsatisfactory treatment response; 
AE ↑
Thailand115 1995–98 RCT 28 Quinine 29 100% Slow PCT; AE ↑
TBB116 1997–2000 RCT 42 Quinine and 
clindamycin
65 100% (99·3–100) Gametocytes ↑; AE ↑; cost ↑
TBB117 1992–96 Observational 42 Artesunate for 
7 days
53 90·6% (81·6–99·6) Eﬃ  cacy <90%
TBB111 1991–96 Observational 42 Meﬂ oquine 194 72% Eﬃ  cacy <90%
TBB112 1995–97 RCT 63 Meﬂ oquine and 
artesunate
65 98·2% (94·7–100) Meﬂ oquine and artesunate eﬀ ective; 
gametocytes ↓
Thailand115 1995–98 RCT 28 Meﬂ oquine and 
artesunate
28 100% AE of meﬂ oquine and artesunate ↓; 
PCT ↓; FCT ↓
TBB118 2000–01 Observational 42 AAP 24 100% Cost ↑↑
TBB114 2001–03 RCT 63 AAP 39 94·9% (81·4–99·1) Well tolerated; eﬀ ective; practical; 
but cost ↑↑
TBB119 2006–07 Observational 63 DHAPPQ 50 92·2% (76·9–97·4) Well tolerated; eﬀ ective; no evidence 
of toxicity
TBB38 2004–06 RCT 42 Artesunate for 
7 days
128 94·9% (91·0–98·8) Well tolerated; eﬀ ective; no evidence 
of toxicity
TBB38 2004–06 RCT 42 AL 125 86·8% (80·5–93·1) Eﬃ  cacy low; unsatisfactory for 
deployment in pregnant women
TBB38 2004–06 Observational 42 Artesunate and 
clindamycin
88 95·4% (90·3–100) Highly eﬃ  cacious in MDR-Pf 
(unpublished)
PNG120 2006 Pharmacokinetic 28 SP and 
chloroquine
13 62% Small sample size
Plasmodium vivax
TBB113 1995–2000 Observational 28 Chloroquine 111 95·5% Chloroquine safe in ﬁ rst trimester
PNG121 2006 Pharmacokinetic 28 SP and 
chloroquine
2 100% Small sample size
RCT=randomised controlled trial. TBB=Thai-Burmese border. AE=adverse eﬀ ects. ↑=increased. PCT=parasite clearance time. ↓=decreased. FCT=fever clearance time. 
AAP=artesunate, atovaquone, and proguanil. DHAPPQ=dihydroartemisinin-piperaquine. AL=artemether-lumefantrine. MDR-Pf=multidrug-resistant Plasmodium falciparum. 
PNG=Papua New Guinea. SP=sulfadoxine-pyrimethamine. *With 95% CI if available. 
Table 5: Eﬃ  cacy studies of antimalarials in pregnancy in the Asia-Paciﬁ c region
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dawn, when they may already be awake and active, 
potentially restricting the protective eﬀ ect of treated 
nets.147 Mosquito repellents with N,N-diethyl-meta-
toluamide (DEET) are safe in pregnancy,148,149 can reduce 
exposure to insect bites,148 and resulted in a non-
signiﬁ cant reduction in the incidence of P falciparum 
infection in pregnant women in one possibly 
underpowered study.142 
Meﬂ oquine chemoprophylaxis gave 86% protection 
against P falciparum and complete protection against 
P vivax infection in a double-blind, placebo-controlled 
study49 at the Thai-Burmese border when meﬂ oquine was 
still fully eﬀ ective. A retrospective analysis of chloroquine 
chemoprophylaxis in pregnant women from Papua New 
Guinea showed that the drug did not reduce placental or 
maternal peripheral blood infection at delivery where 
resistance was high.41,150 In a double-blind, randomised 
controlled trial of chloroquine chemoprophylaxis at the 
Thai-Burmese border,51 prophylaxis prevented P vivax 
episodes, but had no eﬀ ect on P falciparum in pregnancy. 
In Papua New Guinea, prevalence and density of placental 
and maternal peripheral blood parasitaemia did not seem 
to be aﬀ ected by chloroquine chemoprophylaxis during 
pregnancy, but haemoglobin concentration was higher 
after delivery in women who took chloroquine than in 
those who did not.41 Weekly chloroquine prophylaxis 
resulted in poor parasite clearance despite good 
compliance in a longitudinal investigation in Papua New 
Guinea.33 Few pregnant women use chloroquine 
chemoprophylaxis in India, Papua New Guinea, and the 
Solomon Islands.20,34,151 
The only data for intermittent preventive treatment in 
pregnancy from the Asia-Paciﬁ c region are the pharma-
cokinetics of chloroquine and sulfadoxine-pyri methamine 
(three chloroquine tablets every day for 3 days, and one 
sulfadoxine-pyrimethamine dose), which prevented all 
vivax episodes, but ﬁ ve of 13 women had another 
P falciparum infection within 28 days of treatment.120,121 
The rationale of intermittent screening and treatment is 
to screen pregnant women frequently to detect and treat 
malaria parasitaemia at an early stage and use an eﬀ ective 
drug to prevent the repercussions of symptomatic malaria 
in pregnancy. Despite elimination of severe malaria and 
mortality in women who attended every week,48 this 
strategy has not completely prevented the adverse eﬀ ects 
of low birthweight and anaemia. 
Discussion
Malaria in pregnancy in the Asia-Paciﬁ c region contrasts 
with that in Africa because many women are at risk in 
highly heterogeneous transmission settings. Irrespective 
of the number of children they have had, most pregnant 
women have little or no background immunity to malaria, 
so each infection is potentially fatal to mothers or fetuses. 
Prevention and treatment are complicated by diﬀ erent 
vectors, multidrug-resistant parasites (P falciparum and 
P vivax) and suboptimal dosing of antimalarials, such as 
artemether-lumefantrine. P vivax can relapse throughout 
pregnancy when primaquine is contraindicated. The 
reduced birthweight of ﬁ rst-born babies is similar to that 
recorded in Africa, but eﬀ ects of symptomatic malaria in 
pregnancy (maternal death, miscarriage, stillbirth, or 
premature labour) seem to be more prominent in the 
Asia-Paciﬁ c region. Although malaria control and the 
intro duction of artemisinin-based combination therapies 
in the general population has resulted in a substantial 
decline in prevalence of malaria, further eﬀ orts are 
needed from the national malaria control programmes 
Panel: Research priorities in the Asia-Paciﬁ c region
• Regional clinical burden of malaria in pregnancy with 
longitudinal data collection
• Feasibility of early detection (frequent intermittent 
screening) and treatment with eﬀ ective antimalarials 
• Eﬀ ect of submicroscopic Plasmodium falciparum and 
Plasmodium vivax infections on maternal and fetal health
• Pharmacokinetic and drug-dose-optimisation studies in 
diﬀ erent populations, especially for artemether, 
lumefantrine, dihydroartemisinin, and piperaquine
• Eﬃ  cacy of and compliance to quinine (and clindamycin) 
as ﬁ rst-trimester treatment for P falciparum infection, and 
eﬃ  cacy of chloroquine for P vivax infection 
• Eﬀ ect of malaria in pregnancy and antimalarial exposure 
on growth, development, and survival of the fetus, 
newborns, infants, and young children in longitudinal 
cohorts
• Interactions between malaria, red-cell inherited disorders, 
co-infections (eg, helminths, HIV, or rickettsia), and 
nutrient supplementation
• Strategies to prevent malaria (P falciparum and P vivax) in 
at-risk groups such as migrants, or those exposed because 
of occupation or residential location
• Eﬀ ect of malaria in pregnancy on post-partum morbidity 
and mortality
Search strategy and selection criteria
Reports were identiﬁ ed through searches of PubMed for 
those published before Jan 10, 2011, with the terms “malaria” 
and “pregnancy” combined with speciﬁ c country names. The 
analysis was restricted to English language articles. The 
Malaria in Pregnancy Consortium library, WHO regional 
websites, the World Malaria Report, and ClinicalTrials.gov 
were searched for additional studies of malaria in pregnancy 
from included countries. We identiﬁ ed national malaria 
treatment and prevention policies for pregnant women on 
the websites of each country’s Ministry of Health. All regional 
WHO representatives were approached to include available 
data from each national malaria programme. Principal 
investigators of continuing trials in the region were invited to 
share unpublished data.
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and donors, because every infection in pregnancy is 
detrimental to mother and baby, with repercussions in 
infancy and childhood. 
Methods of detection of parasitaemia (peripheral or 
placental malaria smear, rapid diagnostic tests, or 
histopathology) underestimate the burden of malaria in 
pregnancy. Prevalence surveys could show that few 
women are infected at one timepoint, but cumulative 
proportions of malaria infections are more useful 
indicators because of the duration of pregnancy. Of the 
126 reports included in this Review (webappendix p 1–4), 
107 (85%) came from only three countries (Thailand, 
India, Papua New Guinea). In many regions of high 
malaria transmission, no study of malaria in pregnancy 
has been done or reported in English. Likewise, 
pharmacokinetic drug ﬁ ndings need conﬁ rmation in 
distinct populations.
Improved estimates of the morbidity and mortality of 
malaria in pregnancy calculated from longitudinal cohort 
data in populations at risk are urgently needed, as are 
drug-dose-optimisation studies in pregnant women, and 
implementation of strategies for prevention of malaria in 
pregnancy (panel). When malaria in pregnancy cannot be 
readily prevented, accurate diagnosis and prompt 
treatment with eﬃ  cient drugs for any detected 
parasitaemia are essential to avert dangerous symptomatic 
disease and to reduce eﬀ ects on fetuses. Indeed, in a 
recent report of the largest study152 into the eﬀ ects of 
malaria and its treatment in the ﬁ rst trimester, both vivax 
and falciparum malaria contributed signiﬁ cantly to 
miscarriage. Risk of miscarriage was three-times higher 
in women with asymptomatic malaria, and four-times 
higher in those with symptomatic disease, compared with 
women who did not have malaria. No serious side-eﬀ ects 
of antimalarial treatments were noted.152 However, even a 
safe and eﬀ ective 3 day artemisinin-based combination 
treatment for women in the second and third trimester is 
still absent in most countries in the Asia-Paciﬁ c region. 
Evidence suggests that dihydroartemisinin-piperaquine 
is one of the best contenders. The best possible frequency, 
feasibility, and eﬀ ectiveness of intermittent screening in 
the antenatal clinic in diﬀ erent settings should be 
assessed. For example, malaria screening at every 
antenatal visit could be provided to pregnant women at 
increased risk for malaria. More work is needed to address 
the diﬃ  cult question of prevention and treatment of 
P vivax during pregnancy.
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